Genio connects blood donors directly to medical researchers. We don't draw blood — we own the relationships on both sides and take a placement fee. $40K validates the model in 90 days.
Uber doesn't buy cars or get driver's licenses. DoorDash doesn't own restaurants. Genio doesn't draw blood, process specimens, or run labs. We recruit donors, match them to studies, and coordinate logistics through existing infrastructure.
Donor database & relationships. Researcher relationships. AI matching engine. Logistics coordination. The brand on both sides.
Blood draws (partner clinics). Specimen processing (academic core labs). Shipping (existing courier networks). IRB oversight (commercial IRB).
Near-zero fixed costs. No clinical insurance, no OSHA burden, no lab equipment, no phlebotomist payroll. Pure software + logistics margin.
The entire flow from donor sign-up to researcher delivery — orchestrated by Genio, executed by licensed partners.
Meta ads target specific demographics and conditions in the Philly metro. Donors sign up, complete a health profile, and give digital consent via IRB-approved protocol.
AI matches donor profiles to active researcher requests. Blood type, demographics, health conditions, biomarkers — matched in seconds, not weeks.
Donor walks into a local partner clinic for a 15-minute blood draw. The clinic handles the draw, OSHA compliance, and insurance. We pay them a flat per-draw fee.
Blood goes to an academic core lab for processing into 3–5 specimen types (serum, plasma, PBMCs, DNA, RNA). Specimens shipped directly to the researcher.
In 2019, I co-founded a biospecimen company — same concept. COVID killed the timing. But the core insight was right, and everything that was hard then is easy now.
Matching donors to studies required manual data review, human phone calls, and paper consent. The admin cost I was trying to eliminate — I had to recreate it myself. The operation needed 20 employees to do what AI now does in seconds.
AI parses study protocols instantly. Matching donors to eligibility criteria takes seconds. Automated consent, scheduling, and donor communication. One founder with AI tools can run the entire operation.
Sanguine Bio runs direct-to-donor collection with 70,000+ donors, mobile phlebotomy, and pharma clients. But they're B2B fulfillment — no consumer brand, no marketplace. The playbook works. Nobody's built the consumer side.
Existing players either aggregate from biobanks or operate as full-service CROs. Nobody is building a direct-to-donor AI marketplace.
| Traditional CROs | iSpecimen | Genio | |
|---|---|---|---|
| Model | Full-service recruitment | Biobank aggregator marketplace | Direct-to-donor AI marketplace |
| Specimen source | Hospital networks, sites | Existing biobanks | Own donor pool (fresh, on-demand) |
| Cost per specimen | $30,000–$50,000 per patient | $315–$484 avg (SEC filings) | $300–$500 |
| Time to match | 4–8 weeks | 1–3 weeks | < 30 seconds |
| Donor relationship | None (hospital-owned) | None (biobank-owned) | Direct — donors are paid, profiled, retained |
| AI operations | None | Partial | End-to-end |
| Donor incentive | $0 to patient | $0 to patient | $20–$500 per donation |
| Revenue | $B+ (Covance, ICON, PPD) | $3.3M TTM (down 70% from peak, Nasdaq delisting) | Pre-revenue (validating with $40K) |
iSpecimen is the closest comparable — a publicly traded biospecimen marketplace. Their avg selling price is $315–$484/specimen (2024 SEC filings), proving researchers will pay marketplace prices. But they're in freefall: revenue down 70% from $11M peak, Nasdaq delisting notice, -137% operating margin. Why? They don't own the supply.
Their "ready to ship" categories tell us exactly which conditions researchers are buying. We use this as a targeting roadmap for donor acquisition — recruit the people they can't find fast enough.
Other competitors in the space: BioIVT, Cureline, The Sample Network, Novaseek, NDRI. All operate the same old model — source from hospitals and biobanks. None build direct donor relationships. None pay the donor.
iSpecimen just launched an AI matching agent (March 2026) — they're scrambling to modernize. But bolting AI onto a broken supply model doesn't fix the core problem. We're AI-native from day one with a fundamentally better supply chain.
Phase 1 is a validation sprint — one person with AI tools doing the work of a team. Technical co-founder and research sales hire come after the model proves out.
25% equity · $120K pre-money · New entity (Genio LLC)
New entity — Genio LLC. $120K pre-money valuation. Steven retains 75% and goes full-time for 90 days. If it works, revenue from Phase 1 funds Phase 2. No additional capital required.
Four binary questions. If all four are yes, the business is real.
50 draws × 4 specimens × $400 avg = $80,000 revenue against $40K invested. That funds expansion to a second metro, ops hire, and increased ad spend without additional capital.
Every number below comes from published sources: iSpecimen SEC filings, Boston Medical Center lab rates, CHTN commercial pricing, and SFARI biospecimen catalogs. No projections — market prices.
A single draw is processed into multiple specimen types at a partner lab — each matched to a different study. One donor visit generates 3–5 placements.
Phase 1 is funded by $40K investment. Phase 2 is funded by Phase 1 revenue. No additional capital required unless we choose to accelerate.
*No additional capital required if Phase 1 revenue targets are met. If Phase 1 underperforms, scale and timeline adjust accordingly.
Every input is sourced from market data. Specimen pricing from iSpecimen SEC filings ($315–$484 avg). Processing costs from Boston Medical Center and U of Michigan core labs. No fantasy numbers.
| Metric | Conservative | Moderate |
|---|---|---|
| Donors in database | 200 | 500 |
| Active research clients | 2 | 5 |
| Donor draws (Year 1) | 50 | 150 |
| Avg specimens per draw | 3 | 4 |
| Total placements | 150 | 600 |
| Avg revenue per specimen | $350 | $400 |
| Revenue | $52K | $240K |
| Cost per draw (all-in) | $440 | $440 |
| Total COGS | $22K | $66K |
| Gross profit | $30K | $174K |
| Operating expenses | $40K | $80K |
| Net | −$10K | $94K |
Conservative case breaks even. Even with only 50 draws and 2 clients, total loss is $10K. The moderate case — 150 draws, 5 clients — nets $94K profit on $40K invested. Disease-state specimens (cancer, autoimmune) command $500–$1,000+ per specimen, which isn't modeled here.
The #1 investor question for a biospecimen company. We researched this thoroughly using federal regulations, FDA guidance, and real-world precedent.
21 CFR 607.3(d) defines "manufacture" as the physical collection, preparation, processing, or packaging of blood products. Genio does none of this. The partner clinic collects. The academic lab processes. We're software and logistics coordination — not a blood establishment.
iSpecimen (NASDAQ: ISPC) has operated a biospecimen marketplace for over a decade without FDA blood establishment registration. The registered entities are the hospitals and labs in their network — not iSpecimen. Same model as ours.
PA Blood Bank Act Section 19 explicitly exempts "commercial establishments which obtain and process blood products which are never transfused or injected into humans." Research specimens qualify. Our specimens never enter a human body.
The one risk: if we direct the physical operations (specifying exact SOPs, processing parameters, QC requirements), FDA could argue we're a "de facto manufacturer" controlling the process through contractors. The fix is structural: